Context Therapeutics CNTX Stock
Context Therapeutics Price Chart
Context Therapeutics CNTX Financial and Trading Overview
| Context Therapeutics stock price | 0.3 USD |
| Previous Close | 0.34 USD |
| Open | 0.34 USD |
| Bid | 0.23 USD x 200 |
| Ask | 0.4 USD x 200 |
| Day's Range | 0.34 - 0.36 USD |
| 52 Week Range | 0.3 - 3.62 USD |
| Volume | 193.33K USD |
| Avg. Volume | 1.91M USD |
| Market Cap | 31.66M USD |
| Beta (5Y Monthly) | 1.716 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.48 USD |
| Forward Dividend & Yield | N/A (0%) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.03 USD |
CNTX Valuation Measures
| Enterprise Value | -11828036 USD |
| Trailing P/E | N/A |
| Forward P/E | -0.79089296 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 0.8303614 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | 0.243 |
Trading Information
Context Therapeutics Stock Price History
| Beta (5Y Monthly) | 1.716 |
| 52-Week Change | -70.17% |
| S&P500 52-Week Change | 15.77% |
| 52 Week High | 3.62 USD |
| 52 Week Low | 0.3 USD |
| 50-Day Moving Average | 0.44 USD |
| 200-Day Moving Average | 1.56 USD |
CNTX Share Statistics
| Avg. Volume (3 month) | 1.91M USD |
| Avg. Daily Volume (10-Days) | 990.19K USD |
| Shares Outstanding | 91.88M |
| Float | 63.73M |
| Short Ratio | 3.55 |
| % Held by Insiders | 1.57% |
| % Held by Institutions | 68.81% |
| Shares Short | 6.91M |
| Short % of Float | 8.66% |
| Short % of Shares Outstanding | 7.52% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | N/A |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | June 30, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -45.69% |
| Return on Equity (ttm) | -76.14% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -48706952 USD |
| Net Income Avi to Common (ttm) | -45957840 USD |
| Diluted EPS (ttm) | -0.48 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 42.99M USD |
| Total Cash Per Share (mrq) | 0.47 USD |
| Total Debt (mrq) | 244.99K USD |
| Total Debt/Equity (mrq) | 0.64 USD |
| Current Ratio (mrq) | 5.811 |
| Book Value Per Share (mrq) | 0.415 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -33970928 USD |
| Levered Free Cash Flow (ttm) | -31525372 USD |
Profile of Context Therapeutics
| Country | United States |
| State | PA |
| City | Philadelphia |
| Address | 2001 Market Street |
| ZIP | 19103 |
| Phone | 267 225 7416 |
| Website | https://www.contexttherapeutics.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 15 |
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company's product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. It has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Q&A For Context Therapeutics Stock
What is a current CNTX stock price?
Context Therapeutics CNTX stock price today per share is 0.3 USD.
How to purchase Context Therapeutics stock?
You can buy CNTX shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Context Therapeutics?
The stock symbol or ticker of Context Therapeutics is CNTX.
Which industry does the Context Therapeutics company belong to?
The Context Therapeutics industry is Biotechnology.
How many shares does Context Therapeutics have in circulation?
The max supply of Context Therapeutics shares is 91.88M.
What is Context Therapeutics Price to Earnings Ratio (PE Ratio)?
Context Therapeutics PE Ratio is now.
What was Context Therapeutics earnings per share over the trailing 12 months (TTM)?
Context Therapeutics EPS is -0.48 USD over the trailing 12 months.
Which sector does the Context Therapeutics company belong to?
The Context Therapeutics sector is Healthcare.
Context Therapeutics CNTX included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
27193.34 USD — |
-1.25
|
7.83B USD — | 27066.76 USD — | 27491.9 USD — | — - | 7.83B USD — |
|
US Tech Health Care
IXHC
US
|
1285.8 USD — |
-0.77
|
— — | 1265.56 USD — | 1286.72 USD — | — - | — — |
- {{ link.label }} {{link}}
